Concluding from these original findings, we propose that MSRV-Env is a potential therapeutic target in CIDP, at least in a significant proportion of patients, and that it may become a useful blood biomarker along with CXCL10 and IL6. The gene discussed is IL6; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.